Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status-dependent signatures predicting response to immunotherapy in HNSCC warrant further study.
Authors
- Alban J. Linnenbach (ORCID: https://orcid.org/0000-0003-2215-381X)
- Athanassios Argiris (ORCID: https://orcid.org/0000-0003-4075-8812)
- Eric V. Mastrolonardo (ORCID: https://orcid.org/0000-0002-2869-8848)
- Joseph Curry (ORCID: https://orcid.org/0000-0001-9507-4237)
- Angela Alnemri (ORCID: https://orcid.org/0000-0001-5521-6261)
- E. Reilly Scott (ORCID: https://orcid.org/0000-0002-7445-7025)
- Adam Luginbuhl (ORCID: https://orcid.org/0000-0001-7682-3108)
- Anastasia Nikitina (ORCID: https://orcid.org/0000-0002-4321-3693)
- Stacey Gargano (ORCID: https://orcid.org/0000-0002-2780-1866)
- Sruti Tekumalla (ORCID: https://orcid.org/0000-0002-6043-9096)
- Jessica Scher (ORCID: https://orcid.org/0009-0008-6742-0110)
- Matthew Old (ORCID: https://orcid.org/0000-0003-1795-5877)
- Danielle Sookiasian (ORCID: https://orcid.org/0009-0000-5534-6066)
- Benjamin E. Leiby (ORCID: https://orcid.org/0000-0003-0761-8383)
- Mỹ G. Mahoney (ORCID: https://orcid.org/0000-0003-0203-9171)
- Nolan B. Seim (ORCID: https://orcid.org/0000-0002-9227-5313)
- Tingting Zhan (ORCID: https://orcid.org/0000-0001-9971-4844)
- Camilo Henao (ORCID: https://orcid.org/0009-0005-0471-8620)
- Andrew P. South (ORCID: https://orcid.org/0000-0001-7650-0835)
- Владимир Кушнарев (ORCID: https://orcid.org/0000-0003-4608-9349)
- Madalina Tuluc (ORCID: https://orcid.org/0000-0003-4920-3901)
- Pablo Llerena (ORCID: https://orcid.org/0009-0008-1507-9723)
- Ubaldo Martinez‐Outschoorn (ORCID: https://orcid.org/0000-0003-1483-4551)
- Madison Chasse (ORCID: https://orcid.org/0009-0004-9831-8697)
- Jennifer M. Johnson (ORCID: https://orcid.org/0000-0003-4548-307X)
- Anastasia Sobol (ORCID: https://orcid.org/0009-0001-9773-5059)
- David M. Cognetti (ORCID: https://orcid.org/0000-0001-7039-3055)
- George C. Prendergast (ORCID: https://orcid.org/0000-0002-1449-7332)
- Larry A. Harshyne (ORCID: https://orcid.org/0000-0002-8699-3028)
- Christopher J.H. Davitt (ORCID: https://orcid.org/0000-0002-1081-5284)
- Andrey Tyshevich (ORCID: https://orcid.org/0009-0001-9117-3972)
- Victor Jegede (ORCID: https://orcid.org/0000-0001-8383-8818)
- Derek Mann (ORCID: https://orcid.org/0000-0002-1104-8507)
- Kathryn Nunes (ORCID: https://orcid.org/0009-0003-3657-978X)
- Rita Axelrod (ORCID: https://orcid.org/0009-0003-5740-0021)
Institutions
- Thomas Jefferson University (US)
- Lankenau Institute for Medical Research (US)
- Thomas Jefferson University Hospital (US)
- Sidney Kimmel Cancer Center (US)
- Addgene (US)
- The Ohio State University (US)
- Repligen (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0037
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Bristol-Myers Squibb
- National Institutes of Health
- National Cancer Institute